Cargando…

Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis

Introduction  Radiotherapy provides excellent outcome in early stage glottic cancer; however, the optimal radiotherapy dose fractionation remains unknown. Objective  To investigate the outcome of patients with T2N0M0 treated with either hypofractionated (HypoFxn) or conventionally fractionated radic...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovarik, Josef, Kelly, Charles, Cunnell, Michelle, Jamil, Fatima, Iqbal, Muhammad Shahid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Revinter Publicações Ltda. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879650/
https://www.ncbi.nlm.nih.gov/pubmed/36714891
http://dx.doi.org/10.1055/s-0042-1745855
_version_ 1784878738247254016
author Kovarik, Josef
Kelly, Charles
Cunnell, Michelle
Jamil, Fatima
Iqbal, Muhammad Shahid
author_facet Kovarik, Josef
Kelly, Charles
Cunnell, Michelle
Jamil, Fatima
Iqbal, Muhammad Shahid
author_sort Kovarik, Josef
collection PubMed
description Introduction  Radiotherapy provides excellent outcome in early stage glottic cancer; however, the optimal radiotherapy dose fractionation remains unknown. Objective  To investigate the outcome of patients with T2N0M0 treated with either hypofractionated (HypoFxn) or conventionally fractionated radical (ConFxn) radiotherapy. Methods  According to our institutional protocol, patients with T2N0M0 glottic cancer can be treated either with ConfFxn or HypoFxn radiotherapy, as per clinician's and patient's choice, following shared decision making discussing the advantages and disadvantages of both modalities. A total of 77 patients with T2N0M0 squamous cell carcinoma of glottis treated with either HypoFxn 55Gy in 20 fractions ( n  = 19) or ConFxn 63 to 65Gy in 30 fractions ( n  = 58) were included. Results  With median follow-up of 3.4 years, there was no significant difference in disease-free survival (median: HypoFxn = 65.2 months, and ConFxn = 75.3 months; p  = 0.874), local recurrence free survival rates (median: HypoFxn = 78.8 months vs. ConFxn = 81.2 months; p  = 0.274), and overall survival (median: HypoFxn = 65.9 months vs. ConFxn = 67.7 months; p  = 0.532). Elective neck irradiation was given to 43 patients, all in the ConFxn group, and this was associated with poorer local control ( p  = 0.027). The use of radiotherapy modality, three-dimensional conformal radiotherapy (3DRT) versus intensity modulated radiotherapy (IMRT), was not a prognostic factor ( p  = 0.36). In the HypoFxn group, grade III acute dysphagia requiring nasogastric tube was 16%, compared with 25% in the ConFxn group ( p  = 0.446). Conclusion  HypoFxn radiotherapy provides a comparable treatment outcome with acceptable toxicity. The addition of prophylactic irradiation of the neck lymph nodes has no impact on regional control.
format Online
Article
Text
id pubmed-9879650
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Thieme Revinter Publicações Ltda.
record_format MEDLINE/PubMed
spelling pubmed-98796502023-01-27 Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis Kovarik, Josef Kelly, Charles Cunnell, Michelle Jamil, Fatima Iqbal, Muhammad Shahid Int Arch Otorhinolaryngol Introduction  Radiotherapy provides excellent outcome in early stage glottic cancer; however, the optimal radiotherapy dose fractionation remains unknown. Objective  To investigate the outcome of patients with T2N0M0 treated with either hypofractionated (HypoFxn) or conventionally fractionated radical (ConFxn) radiotherapy. Methods  According to our institutional protocol, patients with T2N0M0 glottic cancer can be treated either with ConfFxn or HypoFxn radiotherapy, as per clinician's and patient's choice, following shared decision making discussing the advantages and disadvantages of both modalities. A total of 77 patients with T2N0M0 squamous cell carcinoma of glottis treated with either HypoFxn 55Gy in 20 fractions ( n  = 19) or ConFxn 63 to 65Gy in 30 fractions ( n  = 58) were included. Results  With median follow-up of 3.4 years, there was no significant difference in disease-free survival (median: HypoFxn = 65.2 months, and ConFxn = 75.3 months; p  = 0.874), local recurrence free survival rates (median: HypoFxn = 78.8 months vs. ConFxn = 81.2 months; p  = 0.274), and overall survival (median: HypoFxn = 65.9 months vs. ConFxn = 67.7 months; p  = 0.532). Elective neck irradiation was given to 43 patients, all in the ConFxn group, and this was associated with poorer local control ( p  = 0.027). The use of radiotherapy modality, three-dimensional conformal radiotherapy (3DRT) versus intensity modulated radiotherapy (IMRT), was not a prognostic factor ( p  = 0.36). In the HypoFxn group, grade III acute dysphagia requiring nasogastric tube was 16%, compared with 25% in the ConFxn group ( p  = 0.446). Conclusion  HypoFxn radiotherapy provides a comparable treatment outcome with acceptable toxicity. The addition of prophylactic irradiation of the neck lymph nodes has no impact on regional control. Thieme Revinter Publicações Ltda. 2022-07-11 /pmc/articles/PMC9879650/ /pubmed/36714891 http://dx.doi.org/10.1055/s-0042-1745855 Text en Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Kovarik, Josef
Kelly, Charles
Cunnell, Michelle
Jamil, Fatima
Iqbal, Muhammad Shahid
Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis
title Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis
title_full Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis
title_fullStr Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis
title_full_unstemmed Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis
title_short Hypofractionated (2.75 Gy per fraction) versus Conventionally Fractionated Primary Radiotherapy for T2N0M0 Carcinoma of the Glottis
title_sort hypofractionated (2.75 gy per fraction) versus conventionally fractionated primary radiotherapy for t2n0m0 carcinoma of the glottis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879650/
https://www.ncbi.nlm.nih.gov/pubmed/36714891
http://dx.doi.org/10.1055/s-0042-1745855
work_keys_str_mv AT kovarikjosef hypofractionated275gyperfractionversusconventionallyfractionatedprimaryradiotherapyfort2n0m0carcinomaoftheglottis
AT kellycharles hypofractionated275gyperfractionversusconventionallyfractionatedprimaryradiotherapyfort2n0m0carcinomaoftheglottis
AT cunnellmichelle hypofractionated275gyperfractionversusconventionallyfractionatedprimaryradiotherapyfort2n0m0carcinomaoftheglottis
AT jamilfatima hypofractionated275gyperfractionversusconventionallyfractionatedprimaryradiotherapyfort2n0m0carcinomaoftheglottis
AT iqbalmuhammadshahid hypofractionated275gyperfractionversusconventionallyfractionatedprimaryradiotherapyfort2n0m0carcinomaoftheglottis